Notably, HGC is a newly developed HDAC6 inhibitor, which improves dopaminergic neuron viability and attenuates behavioral defects in PD-modeling cells and animals by the accumulation of K28 acetylation in NADH-ubiquinone-oxidoreductase flavoprotein 1 (NDUFV1), and thus maintaining mitochondrial integrity and functions [116]. Here, HDAC6 is linked to Parkinson disease.